Biotech Investing
NOTES: BioAge Labs — BioAge’s Senolytic Insolvency: Refinancing Death
BioAge Labs is running a biological grift. They are refinancing the Hayflick limit with a glorified anti-inflammatory while ignoring the compounding debt of cellular aging. A forensic look at their massive burn rate and missing Phase 3 capital.